Swiss clinical-stage biotech with IP assets based on proprietary technologies for addressing various Orphan and Non-Orphan therapeutic indications in dermatology, ENT and GI.
Since 2009, this privately funded firm run by a team of seasoned executives has followed a virtual business model of in-licensing promising biologics and devices, outsourcing the required development, regulatory and manufacturing services and out-licensing commercialization to corporate partners.
To date, three proprietary technology platforms have been developed. These platforms provide a strong basis for a strategy around fast market access, whether as an orphan drug, a medical device or as a cosmetic product.
Contact us to get details about this Swiss medical devices and biotech company for sale
The current pipeline consists of seven biopharmaceuticals, three medical devices and two non-prescription, health products.
The biopharmaceutical pipeline includes a Phase III oral mucositis development with orphan designation and two Phase II products; one orphan drug for mucosae inflammation and another non-orphan drug for GI ulceration. Two other products are at clinical stage for three different orphan therapies. In total, half the medical products are aimed at Orphan indications addressing unmet needs.
The medical device pipeline targets migraine, chronic sinus and cancer therapy-induced wounds with another proprietary technology platform.
One of the two cosmetic products –an anti-aging product- will be in the market at end 2018. The second, a topical treatment for dermatological disorders is still at a research stage.
Feel free to contact us for more information regarding this Swiss Clinical-stage Biotechnology / Medtech Company. If this pharma company for sale does not fit your requirements feel free to ask for other companies from pharma business in the section pharma companies for sale. For a review of pharma buyers please visit section pharma companies wanted.
Note: CFIE only works with formal companies. We do get a lot of requests and it is difficult to follow up on all inquiries from visitors to our website. For each company, we assess the likelihood of a future transaction. We only get back to you if we see a realistic opportunity to do a future acquisition or business sale. In order to increase your chances of receiving a reply as an individual, please explain as much as possible about your personal background, strategy and fit with the target. There is also a possibility that your details will be kept on file and we will get back to you once there is an opportunity to do a transaction. CFIE can’t guarantee you will receive an answer to your request.